Brimonidine battle begins with B&L launch

Webb, Jennifer A.
July 2003
Ophthalmology Times;7/15/2003, Vol. 28 Issue 14, p10
Trade Publication
Focuses on the release of the generic version of brimonidine tartrate ophthalmic solution in Rochester, New York. Approval of the solution by the Food & Drug Administration; Exclusivity of the drug; Availability of brimonidine tartrate alternative.


Related Articles

  • Generics: Not All Drugs Are Created Equal. Cantor, Louis B.; Lee, David A.; Netland, Peter A. // Review of Ophthalmology;Jan2002, Vol. 9 Issue 1, p72 

    Evaluates the effectiveness of generic ophthalmic drugs. Categorization of pharmaceuticals; Concerns about generic ophthalmic drugs; Bioequivalence of generic and brand name ophthalmic drugs. INSET: Evolution of United States Generic Drug Policy.

  • When Generic Drugs Are Not the Right Rx. Fiscella, Richard G. // Review of Optometry;8/15/2002, Vol. 139 Issue 8, p51 

    Explains how ophthalmic generic drugs may differ from branded products. Problems with generic ophthalmic products; Overview of the Drug Price Competition and Patent Term Restoration Act; Assessment of drug pharmacokinetics and bioaequivalence; Examples of generic products that have not lived up...

  • Generic glaucoma drugs may not offer same effect as brand. Guttman, Cheryl // Ophthalmology Times;4/1/2002, Vol. 27 Issue 7, p1 

    Reveals that there is insufficient data to determine whether generic glaucoma drugs are equivalent in efficacy and safety relative to the reference legend drug. Economic impact of generic prescribing; Establishment of generic equivalency of ophthalmic products.

  • Generics: Friend or Foe? Bowling, Ernie // Review of Optometry;2/15/2011, Vol. 148 Issue 2, p82 

    The article provides information concerning generic medications, highlighting the crucial role of optometrists to consider ophthalmic generics' therapeutic efficacy and safety characteristics before conducting treatment in the U.S. It mentions the acceptance and usage of generic medications in...

  • Topical Ophthalmic Generics: They're Back. Jackson, Mitch // Review of Ophthalmology;Jun2010, Vol. 17 Issue 6, p67 

    The article discusses the re-emergence of topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAID) generics despite the voluntary recall of generic diclofenac a decade ago. The cost benefit is singled out as one of the reasons of the re-emergence. It mentions that the newest NSAID out in...

  • Generic medications in ophthalmology. Zore, Matt; Harris, Alon; Tobe, Leslie Abrams; Siesky, Brent; Januleviciene, Ingrida; Behzadi, Jennifer; Amireskandari, Annahita; Egan, Patrick; Garff, Kevin; Wirostko, Barbara // British Journal of Ophthalmology;Mar2013, Vol. 97 Issue 3, p253 

    The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of...

  • Generic latanoprost may improve patients adherence with lower costs vs. brand-name agents. Kahl, Kristie L. // Ocular Surgery News;7/10/2015, Vol. 33 Issue 13, p25 

    The article discusses research being done on the benefit of switching to genetic latanoprost in improving patient adherence in the treatment of open-angle glaucoma. It references a study by Joshua D. Stein et al. published in the journal "Ophthalmology." Topics covered include the use of...

  • To what extent does a lack of refrigeration of generic chioramphenicol eye-drops used in India decrease their purity and what are the implications for Europe? Aboshiha, J.; Weir, R.; Singh, P.; Ewings, P.; Lovering, A. // British Journal of Ophthalmology;May2008, Vol. 92 Issue 5, p609 

    Background/aims: Thermal degradation of chloramphenicol occurs at a faster rate when stored in unrefrigerated conditions. This study measures the concentration of the principal thermal breakdown product of generic chloramphenicot eye-drops being sold over the counter in chemists in different...

  • Press FDA to balance disparities among branded drugs, generics. DePaolis, Michael D. // Primary Care Optometry News;May2014, Vol. 19 Issue 5, p3 

    The article discusses the inequalities between branded and generic medications for use in eye care and the steps taken by the U.S. Food and Drug Administration to address this issue since the Waxman-Hatch Act in 1984.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics